Private practice with Dr Seth BilazarianView all posts »
ARBITER 6-HALTS: What are the clinical implications?Nov 18, 2009 12:45 EST
In this trial extended-release niacin was shown to be superior to ezetimibe with a surrogate endpoint of carotid IMT. As we wait for more complete data from the AIM-HIGH and IMPROVE-IT trials, how will the results of ARBITER 6-HALTS affect your daily practice? Will you use potent statins more and zetia less while we wait until 2012 for the IMPROVE-IT study?